Endocrine Abstracts

Whilst surgery and external beam radiotherapy remain cornerstones of the management of acromegaly, recent guidelines have emphasised the importance of adjunctive medical therapy [e.g. with somatostatin receptor ligands (SRLs), dopamine agonists, growth hormone (GH) receptor antagonists] in attaining 'safe' GH and insulin like growth factor 1 (IGF-1) levels, especially in patients who are not 'cured' following primary intervention. Several studies have established the efficacy ...